Global External Neurostimulation Device Market Size By Type (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation), By Application (Hospitals and clinics, Ambulatory Surgery...

The Global External Neurostimulation Device Market was valued at USD 4.6 billion in 2023 and is projected to surpass USD 9.4 billion by 2031, growing at a CAGR of 9.2% from 2023 to 2031. The growth of this market is driven by the increasing prevalence of neurological disorders, growing demand for non-invasive pain management solutions, and technological advancements in neurostimulation devices. External neurostimulation offers a safe, non-surgical treatment alternative for conditions such as chronic pain, depression, epilepsy, and migraines, contributing to its widespread adoption globally.

Drivers:

1. Rising Prevalence of Neurological Disorders:

The increasing incidence of chronic neurological conditions like Parkinson’s disease, epilepsy, and chronic pain is fueling the demand for advanced therapeutic alternatives. External neurostimulation offers a viable and effective solution, driving market growth.

2. Preference for Non-Invasive Treatment Options:

Patients and healthcare providers are increasingly favoring non-invasive treatments to avoid surgical risks and reduce recovery times. This trend significantly boosts the adoption of external neurostimulation devices, particularly in outpatient and homecare settings.

3. Technological Innovations in Device Design:

Continuous advancements in wearable and wireless neurostimulation technologies are enhancing device portability, battery life, and efficacy. Features such as mobile connectivity and app-based controls are attracting broader user bases, improving adherence and patient outcomes.

Restraints:

1. High Cost of Devices and Therapy:

Despite their benefits, external neurostimulation devices can be expensive, especially in regions with limited insurance coverage. This cost barrier may hinder adoption, particularly in low- and middle-income countries.

2. Limited Clinical Evidence for Some Applications:

While clinical trials have validated many neurostimulation uses, the efficacy for newer applications such as anxiety and tinnitus remains under investigation. This limited evidence may restrict market penetration in certain therapeutic areas.

Opportunity:

1. Expanding Applications in Mental Health and Rehabilitation:

Emerging uses of neurostimulation for treating depression, PTSD, and stroke rehabilitation present substantial growth opportunities. The integration of external devices in neuro-rehabilitation programs is expected to rise significantly over the forecast period.

2. Growth Potential in Emerging Markets:

Rising healthcare expenditure, improving neurological care infrastructure, and greater awareness in Asia-Pacific, Latin America, and the Middle East create untapped opportunities for market expansion.

Market by System Type Insights:

Based on system type, the Transcutaneous Electrical Nerve Stimulation (TENS) segment dominated the market in 2023, driven by its widespread use in chronic pain management. TENS devices are favored for their affordability, portability, and ease of use. The External Vagus Nerve Stimulation (VNS) segment is anticipated to witness the fastest growth owing to increasing evidence of its effectiveness in treating depression and epilepsy.

Market by End-use Insights:

By end-use, the Homecare segment held the largest market share in 2023. The convenience of at-home therapy and the rising prevalence of chronic pain conditions among aging populations contribute to this trend. Hospitals and specialty clinics are also significant end-users, especially for advanced and supervised therapies involving complex neurostimulation protocols.

Market by Regional Insights:

North America led the global market in 2023 due to its high prevalence of neurological disorders, strong healthcare infrastructure, and favorable reimbursement policies. Europe follows closely, supported by increasing awareness and technology adoption. Meanwhile, the Asia-Pacific region is expected to register the fastest growth, driven by growing healthcare investments and expanding access to neurological treatments in countries like China, India, and South Korea.

Competitive Scenario:

Key players in the Global External Neurostimulation Device Market include Medtronic plc, Boston Scientific Corporation, NeuroMetrix, Inc., Nevro Corp., Omron Healthcare, Inc., Zynex, Inc., Bioness Inc., and Cefaly Technology. These companies focus on R&D, strategic partnerships, and regulatory approvals to expand their portfolios.

In 2023, Medtronic launched its next-generation wearable VNS device integrated with AI-based monitoring for epilepsy patients.

Nevro Corp. announced a partnership in 2024 to develop customized external neurostimulators for diabetic neuropathy.

Omron Healthcare introduced an app-controlled TENS device tailored for home users in early 2025.

Scope of Work – Global External Neurostimulation Device Market

Report Metric Details

Market Size (2023) USD 4.6 billion

Projected Market Size (2031) USD 9.4 billion

CAGR (2023–2031) 9.2%

Market Segments System Type (TENS, VNS, Others), End-u